In this context, due to the sensitivity of CRC to anti‐angiogenic therapy, novel drugs killing TAMs, such as trabectedin, anti‐PD‐L1 antibodies, a pro‐apoptotic peptide M2 and PLX3397 (CSF‐1R tyrosine kinase inhibitor), might be evaluated in clinical trials as a new anti‐angiogenic strategy 59, 61, 62, 63, 64, 65, 66. The gene discussed is CSF1R; the disease is colorectal carcinoma.